A new study of 100,000 patients shows a small, but significant reduction in cancer in patients who take daily aspirin.
There was a 16% reduction in aspirin-takers…..mostly affecting colon and intestinal tract cancers, liver cancer, and bladder cancer.
This benefit is statistically small, but fits in with the larger picture for aspirin as a beneficial agent in reducing inflammation and intervening with cancer cell development and propogation.
Aspirin is celebrating it’s 100th anniversary of production by Bayer, inc…..and was released the same year as Bayer’s other expected blockbuster…….Herion (that part of the story didn’t turn out as well!)
Read more about this study and it’s importance here, in the JNCI:
http://jnci.oxfordjournals.org/content/early/2012/08/10/jnci.djs338.full